These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9823312)

  • 1. Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells.
    Hiltbold EM; Ciborowski P; Finn OJ
    Cancer Res; 1998 Nov; 58(22):5066-70. PubMed ID: 9823312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies.
    Brossart P; Heinrich KS; Stuhler G; Behnke L; Reichardt VL; Stevanovic S; Muhm A; Rammensee HG; Kanz L; Brugger W
    Blood; 1999 Jun; 93(12):4309-17. PubMed ID: 10361129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells.
    Hiltbold EM; Alter MD; Ciborowski P; Finn OJ
    Cell Immunol; 1999 Jun; 194(2):143-9. PubMed ID: 10383817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses.
    Barratt-Boyes SM; Vlad A; Finn OJ
    Clin Cancer Res; 1999 Jul; 5(7):1918-24. PubMed ID: 10430099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
    Soares MM; Mehta V; Finn OJ
    J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA.
    Dörfel D; Appel S; Grünebach F; Weck MM; Müller MR; Heine A; Brossart P
    Blood; 2005 Apr; 105(8):3199-205. PubMed ID: 15618468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.
    Pietersz GA; Li W; Osinski C; Apostolopoulos V; McKenzie IF
    Vaccine; 2000 Apr; 18(19):2059-71. PubMed ID: 10706970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intercellular and intracellular events following the MHC-unrestricted TCR recognition of a tumor-specific peptide epitope on the epithelial antigen MUC1.
    Magarian-Blander J; Ciborowski P; Hsia S; Watkins SC; Finn OJ
    J Immunol; 1998 Apr; 160(7):3111-20. PubMed ID: 9531265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice.
    Heukamp LC; van der Burg SH; Drijfhout JW; Melief CJ; Taylor-Papadimitriou J; Offringa R
    Int J Cancer; 2001 Feb; 91(3):385-92. PubMed ID: 11169964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma.
    Henderikx P; Kandilogiannaki M; Petrarca C; von Mensdorff-Pouilly S; Hilgers JH; Krambovitis E; Arends JW; Hoogenboom HR
    Cancer Res; 1998 Oct; 58(19):4324-32. PubMed ID: 9766660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1.
    Tsang KY; Palena C; Gulley J; Arlen P; Schlom J
    Clin Cancer Res; 2004 Mar; 10(6):2139-49. PubMed ID: 15041735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
    Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
    Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice.
    Koido S; Tanaka Y; Chen D; Kufe D; Gong J
    J Immunol; 2002 Mar; 168(5):2111-7. PubMed ID: 11859096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
    Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
    Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes.
    Agrawal B; Krantz MJ; Reddish MA; Longenecker BM
    Int Immunol; 1998 Dec; 10(12):1907-16. PubMed ID: 9885912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice.
    Ryan SO; Vlad AM; Islam K; Gariépy J; Finn OJ
    Biol Chem; 2009 Jul; 390(7):611-8. PubMed ID: 19426130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential expression of MUC1 on transfected cell lines influences its recognition by MUC1 specific T cells.
    Magarian-Blander J; Hughey RP; Kinlough C; Poland PA; Finn OJ
    Glycoconj J; 1996 Oct; 13(5):749-56. PubMed ID: 8910002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor regression by CD4 T-cells primed with dendritic/tumor fusion cell vaccines.
    Koido S; Enomoto Y; Apostolopoulos V; Gong J
    Anticancer Res; 2014 Aug; 34(8):3917-24. PubMed ID: 25075013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.